Celldex - Impfstoffe und neue Therapien in Zeiten von Krebs und Pandemien... (Seite 168)

[Macrocosmonaut [Blogger]]

Antwort auf Beitrag Nr.: 23.465.902 von GulOcram am 16.08.06 12:01:03

Zur Abwärtstrendliniendiskussion nun einige klärende Worte:

Klarheit verschafft hier, der zeitunabhängige P&F Chart (traditioneller three low box reversal chart).

Danach gibt es den von ihnen beschriebenen Abwärtstrend aus dem Jahre 1995 nicht - vielmehr hat der Wert seit Mitte 2005 einen intakten Aufwärtstrend entwickelt mit entsprechendem Volumensignal.

Price objective liegt bei 6 US$. (was meines Erachtens eine erste Kurszielmarke auf mittlere Sicht wäre) - höhere Kursziele sind langfristig freilich nicht ausgeschlossen (ATH war bei knapp 20 US$)

In der zurückliegenden Woche hat sich ein morning star reversal im daily Chart ausgebildet.

Im weekly ein dragon fly doji.

Passend dazu ein PPO- Kaufsignal auf Wochenbasis.

Die tertiärzyklische Abwärtsbewegung vom März ist nicht Volumengestützt, was auf ein fragile Trendstabilität dieser Konsoldierungsbewegung im Makrochart hinweist. Wellentechnisch werte ich die Bewegung von Mitte März bis Mitte dieser Woche als wave 2 innerhalb ds Beginns einer langfristigen steigenden Zyklusstruktur.

Frei nach Gann habe ich mir deshalb gestern einen Block ins Depot gelegt.

Wie immer meine eigene Einschätzung und ohne Gewähr. Die gmachten Angaben stellen keine Handelsaufforderung dar - Aktien können steigen oder fallen. Jeder Investor handelt auf eigenes Risiko.

Macrocosmonaut.

[avant_immuno]

Ein kleiner Hoffnungsschimmer für die geplagten Avant-Aktionäre:

heute kleines Plus von 5%

[avant_immuno]

Die Meldung des Tages:

INSIDER kaufen AVANT Aktien.

CEO U. Ryan kauft rund 30.000 Aktien
CFO C. Catlin kauft rund 5.000 Aktien

Dieses Mal sind es richtige Käufe, die aus der eigenen Tasche finanziert wurden. Ansonsten waren es immer nur Gratis-Optionen oder Gratis-Aktien.

Vielleicht ein gutes Zeichen. Wir werden sehen.

Als nächstes erwarte ich folgende News:
- Partner für TP10
- Partner für CETI
- Anthrax Update
- Therapore P1 Resultate
...und noch einiges mehr

[GulOcram]

Der Kurs hat aber dennoch dreimal an der oberen langfristigen Trendlinie halt gemacht.
Aber wir sind ja hier nicht in erster Linie wegen der Charttechnik investiert. Die soll nur Mittel zum Zweck sein, um günstiger rein und rauszukommen. Aber das ist ja bei uns wie ich hier interpretiere nicht an der Zeit.

[Macrocosmonaut [Blogger]]

Also den Ausbruch im Jahre 2000 bis 2002 aus ihrem Abwärtstrend als "kleine" Bullenfalle zu bezeichnen (immerhin verzehnfachte sich der Wert unter hohem Handelsvolumen und überschritt auch ihre Hochs aus den 90`ern für fast 3 Jahre!!!) - halte ich schon für arg vermessen...

Der Ausbruch in 2000 war signifikant - daher ist ihre Trendlinie regelwidrig.

Wenn sie die Linien einzeichnen dann stellen sie fest das der ert einen "kiss back" an die alte gebrochene sekundärzyklische Abwärtstrendlinie aus 2003 vollzogen hat.

Wie auch immer - jedem seine Sicht der Dinge - fundamentale Überlegungen mal vollkommen ausgblendet.

Wie immer meine eigene Einschätzung und ohne Gewähr.

Macrocosmonaut.

[GulOcram]

Antwort auf Beitrag Nr.: 23.465.128 von Macrocosmonaut am 16.08.06 11:16:44

Ich habe den linearen logarithmischen Chart nach meinen Schmalspurkenntnissen analysiert. Und da sehe ich einen Abwärtstrend, wenn man die Lows 1997, 1999 und mitte 2002 verbindet. Parallel verläuft meine obige Trendlinie über die Highs Ende 1995, 1998, 2003 und 2006.
Wohlgemerkt mit einem Ausbruch 2000 bis 2002 (kleine Bullenfalle .)
Über das Top Anfang 2000 und 2004 ergibt sich ein starker Abwärtstrendkanal nach unten. Die untere Trendkanallinie verläuft über das High 1998, 1999 sowie das Low Mitte 2002. Von dieser doppelten Unterstützung 2002 hat sich ein Aufwärtrend gebildet (Mitte 2005), der aber leider kürzlich nach unten durchbrochen wurde. Der starke Abwärtstrend ist aber auch mittlerweile verlassen worden.
Charttechnisch ist der Wert m.E. ein bißchen angeschlagen. Aber solche Werte leben ja von news. Und ein bißchen mehr Umsatz könnte auch nicht schaden. Aber das kommt ja zwangsläufig, wenn man was gescheites entwickelt.

[Macrocosmonaut [Blogger]]

Antwort auf Beitrag Nr.: 23.250.909 von GulOcram am 31.07.06 09:30:21

Lineare Chart:

http://finance.yahoo.com/q/bc?s=AVAN&t=my&l=off&z=m&q=c&c=

Log Chart:

http://finance.yahoo.com/q/bc?s=AVAN&t=my&l=on&z=m&q=c&c=

Na dann - zeichnen Sie mal ein - meines Erachtens ein langfristiger Boden der sich da ausgebildet hat - Kursziele auf lange Sicht bleiben unverändert.

Ich hoffe, das AVAN - in Anbetracht der aktuellen Marktkapitalisierung vorher nicht übernommen wird.

UBS hält mehr als 1 Million Aktien bei AVAN - nachzulesen bei nasdaq.com

Wie immer sind alle Angaben ohne Gewähr.

Macro.

[Macrocosmonaut [Blogger]]

Eine interessante Vereinbarung die Avant da mit Coley Pharmaceuticals da eingegangen ist:

http://wachovia.mworld.com/m/m.w?lp=GetStory&NewsID=21023660…


Ich hatte bereits vor 6 Jahren bei Coley - konkret bei Herrn Michael Stein in den USA - angefragt, inwieweit man dort einsteigen kann. Vorraussetzung war aber damals eine Mindesteinlage von 1 Million US$. Das Unternehmen hatte damals seinen Unternehmenssitz in Hilden, ist aber was Europa angeht mittlerweile in Langenfeld gelandet.

War bereits vor 3 Monaten dort gewesen - werde aber jetzt nochmals anfragen wegen Vaximmune.

Coley selber ist mir derzeit zu teuer - ich habe den Wert aber auf meiner Watchlist - für den Fall, dass er mal "abstürzt" - so wie AVAN seinerzeit.

Auf alle Fälle tut sich jetzt auch was auf dem Cholesterolmarkt - äusserst interessante Entwicklung bei der CETI-Vaccine.

Mal sehen - was sich dort noch tut - habe den Impfstoff zwar nicht auf der Agenda stehen, aber Avant ist ja immer für eine Überraschung gut.

Wie immer sind alle Angaben ohne Gewähr.

Macro.

[Macrocosmonaut [Blogger]]

Antwort auf Beitrag Nr.: 23.290.295 von Plaste am 02.08.06 23:13:39

Die Zahlen sind in Ordnung und haben keine negative Überraschung schweren Ausmasse gebracht.

Was gefällt sind die mehr als 50 Millionen US$ cash beim Unternehmen und was noch mehr gefällt ist, dass Bill Gates 21 Millionen US$ für die Cholerastudie zur Verfügung stellt.

Auch was die anderen Studien angeht, so hört sich das ganze sehr gut an.

Rotarix wirft auch bereits erste "bescheidene" Erträge ab - hier rechne ich aber damit dass sich die Royalities drastisch erhöhen werden, wenn der Verkauf erstmal richtig ans laufen gekommen ist.

Solides Zahlenwerk mit zusätzlich 21 Millionen US$ garniert.

Danke Herr Gates, Danke Mr. Buffet.

Wie immer meine eigene Einschätzung und ohne Gewähr.

Macrocosmonaut.

[Plaste]

Nachdem ich ja immer wieder was von Alleinunterhaltern lese, möchte ich nur sagen: "ich lese öfter fleißig mit"
Und hier die News von Heute:

AVANT's CholeraGarde(R) Vaccine Development Program Receives Further Funding from the Gates Foundation; New Support Follows Successful Phase 2 Clinical Trials

NEEDHAM, Mass.--(BUSINESS WIRE)--Aug. 2, 2006--AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today announced that the International Vaccine Institute ("IVI") has received $21 million in funding from the Bill & Melinda Gates Foundation for a Cholera Vaccine Initiative (CHOVI), which will include conducting further clinical trials of CholeraGarde(R), AVANT's cholera vaccine. Under the direction of John D. Clemens, M.D., IVI plans to conduct Phase 2 and Phase 3 clinical trials of CholeraGarde(R) in Bangladesh and India beginning in 2007. IVI will be purchasing clinical materials produced at AVANT's Fall River, MA manufacturing facility for the trials.

"Cholera is a devastating disease in the developing world," said Una S. Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapeutics, Inc. "We are very pleased to build on the success of our previous Phase 2 clinical trial by continuing our partnership with the IVI for the development of CholeraGarde(R) vaccine. The development of a safe and effective cholera vaccine is important for protecting residents, travelers and military personnel from cholera in endemic areas. We see the initiation of these trials as serving the dual role of addressing a significant health issue in the developing world and advancing development of AVANT's vaccine franchise. We expect to initiate our own Phase 3 study of CholeraGarde(R) in early 2007 to support an application for U.S. and E.U. approval for use in travelers and military personnel."

IVI is founded on the belief that the health of children in developing countries can be dramatically improved by the development, introduction and use of new and improved vaccines and these vaccines should be developed through a dynamic interaction among science, public health and business. The IVI's earlier collaborations with AVANT were supported by the Diseases of the Most Impoverished (DOMI) Program, which was also funded by the Bill & Melinda Gates Foundation. The current CHOVI program will include the development of CholeraGarde(R) as well as an oral killed whole cell cholera vaccine from Vietnam.

"I am pleased to see continued clinical development of the CholeraGarde(R) vaccine for use in endemic regions," stated John D. Clemens, M.D., Director of the International Vaccine Institute. "Our partnership with AVANT underscores IVI's mission of accelerating vaccine development to relieve the burden of disease in developing countries. IVI works with vaccine partners like AVANT to pursue vaccine development that otherwise may not occur."

AVANT is developing a series of oral, single-dose bacterial vaccines to prevent diarrhea and dysentery in travelers and military personnel in developed countries and in people living in developing countries with high rates of water and food borne diseases. In addition to the CholeraGarde(R) vaccine, AVANT's Ty800 typhoid fever vaccine is in a Phase 1/2 clinical trial sponsored by the National Institutes of Health. In preclinical development, AVANT is advancing a vaccine against enterotoxigenic E. coli (ETEC), the most common form of travelers' diarrhea, and a Shigella sonnei vaccine, aimed at the Shigella strain most often contracted by travelers and associated with domestic outbreaks in the United States. Many of these vaccines could also meet the healthcare requirements of less developed countries, where the need for vaccines against water- and food-borne diseases is particularly acute.

About AVANT Immunotherapeutics, Inc.

AVANT Immunotherapeutics, Inc. discovers and develops innovative vaccines and therapeutics that harness the human immune system to prevent and treat disease. Six of AVANT's products are in clinical development, including a treatment to reduce complement-mediated tissue damage associated with cardiac bypass surgery and a novel vaccine for cholesterol management. AVANT is also developing a pipeline of bacteria-fighting products for biodefense, travelers' vaccines, and global health needs based on AVANT'S rapid-protecting, single-dose, oral and temperature stable vaccine technology.

Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: http://www.avantimmune.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements which reflect AVANT's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe", "expect", "anticipate", "intend", "estimate", "project" and similar expressions which do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to: (1) the integration of multiple technologies and programs; (2) the ability to adapt AVANT's vectoring systems to develop new, safe and effective orally administered vaccines against anthrax and plague or other bioterrorism threats or emerging health care threats; (3) the ability to successfully complete development and commercialization of TP10, CETi-1, AVANT's CholeraGarde(R) Vaccine Development Program Receives Further Financial Support from the Gates Foundation CholeraGarde(R) (Peru-15), Ty800 and other products; (4) the cost, timing, scope and results of ongoing safety and efficacy trials of TP10, CETi-1, CholeraGarde(R) (Peru-15), Ty800 and other preclinical and clinical testing; (5) the ability to successfully complete product research and further development, including animal, pre-clinical and clinical studies of TP10, CETi-1, CholeraGarde(R) (Peru-15), Ty800 and other products; (6) the ability of the Company to manage multiple late stage clinical trials for a variety of product candidates; (7) the volume and profitability of product sales of Megan(R)Vac 1, Megan(R)Egg and other future products; (8) the process of obtaining regulatory approval for the sale of Rotarix(R) in major commercial markets, as well as the timing and success of worldwide commercialization of Rotarix(R) by our partner, GlaxoSmithKline; (9) changes in existing and potential relationships with corporate collaborators; (10) the availability, cost, delivery and quality of clinical and commercial grade materials supplied by contract manufacturers; (11) the timing, cost and uncertainty of obtaining regulatory approvals to use TP10, CETi-1, CholeraGarde(R) (Peru-15) and Ty800, among other purposes, for adults undergoing cardiac surgery, to raise serum HDL cholesterol levels and to protect travelers and people in endemic regions from diarrhea causing diseases, respectively; (12) the ability to obtain substantial additional funding; (13) the ability to develop and commercialize products before competitors; (14) the ability to retain certain members of management; and (15) other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

CONTACT: AVANT Immunotherapeutics, Inc.
Una S. Ryan, Ph.D., 781-433-0771
President and CEO
or
Avery W. Catlin, 781-433-0771
Chief Financial Officer
[e-mail]
or
For Media:
Kureczka/Martin Associates
Joan Kureczka, 415-821-2413
[e-mail]

SOURCE: AVANT Immunotherapeutics, Inc.


AVANT Immunotherapeutics Reports Second Quarter and Six-Month Financial Results

NEEDHAM, Mass., Aug 02, 2006 (BUSINESS WIRE) -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today reported a net loss of $5.7 million, or $.08 per share, for the second quarter of 2006 compared to a net loss of $4.7 million, or $.06 per share, for the second quarter of 2005. For the six months ended June 30, 2006, AVANT reported a net loss of $8.6 million, or $.12 per share, compared to a net loss of $9.6 million, or $.13 per share, for the six months ended June 30, 2005. AVANT reported cash and cash equivalents of $53.5 million at June 30, 2006.

Una S. Ryan, Ph.D., AVANT's President and Chief Executive Officer, said, "These financial results were consistent with our expectations and we remain on track in all of our product development programs. AVANT is also in a solid financial position to continue to advance these programs and to build on our industry-leading bacterial vaccine franchise, especially following the receipt of $42.6 million in total milestone payments related to the European approval and commercial launch of the Rotarix(R) rotavirus vaccine.

"During the remainder of 2006, we will be advancing our lead vaccine program, CholeraGarde(R), towards a Phase 3 trial in early 2007 as well as preparing to initiate human safety studies of our oral plague vaccine in early 2007" Dr. Ryan said.

The increased loss for the second quarter of 2006 compared to the same period in 2005 primarily reflected a decrease in revenues combined with an increase in operating expense, offset in part by an increase in investment income. The decrease in revenues primarily reflected lower billing levels to DynPort Vaccine Company LLC (DVC) for the anthrax/plague vaccine contract during the second quarter of 2006. The increase in operating expense is primarily due to increased operating expenses of the Fall River manufacturing facility, TP10 contract manufacturing costs incurred for process development and scale-up work, offset by a reduction in clinical trials costs. The increase in operating expenses further resulted from an increase in general and administrative expenses partly offset by an increase in investment income.

The six-month results for 2006 reflect a decrease in net loss compared to the same period in 2005. This decrease in net loss primarily reflected an increase in revenue and an increase in investment income, offset in part by an increase in operating expense. Product development and licensing revenue of $2.6 million was recorded in the first quarter of 2006 due to the receipt of a milestone payment from GlaxoSmithKline. AVANT also recognized approximately $550,000 in revenue related to PRF Vaccine Holdings LLC's (PRF) purchased interests in the net royalties that AVANT receives from Rotarix(R) worldwide net sales. The decrease in government contracts and grants revenue in 2006 compared to 2005 primarily reflects reduced levels of vaccine development work billable to DVC in 2006.

The increase in operating expense in 2006 compared to 2005 was primarily a result of an increase in research and development expense due to increases in research and development personnel and related costs, consultant fees, contract research costs, license fees, and non-personnel operating and facility-related costs associated with operations of the Fall River facility These increases were offset in part by declines in contract manufacturing costs incurred for process development and scale-up work and clinical trials costs, both associated with the TP10 program. The increase in operating expenses also resulted from higher general and administrative expenses, primarily due to increases in personnel-related expenses and professional services costs. AVANT had higher investment income in 2006 primarily reflecting higher cash balances and higher interest rates between periods.

The $40 million milestone payment received from PRF during the first quarter of 2006 resulted in taxable income for AVANT. The regular taxable income generated by this transaction will be fully offset with available federal and state net operating loss carryforwards. AVANT recorded a provision of $372,000 in the first quarter of 2006 for the alternative minimum tax that will result from receipt of this milestone.

Marketed Programs

Glaxo received European Union (EU) approval for Rotarix(R) in February. Addressing a worldwide market opportunity estimated by Glaxo at $1.8 billion, Rotarix(R) has now been approved in over 65 markets worldwide, including Brazil where a publicly funded mass vaccination of the pediatric population began earlier this year. It has been reported that Glaxo will file for market approval in the United States in early 2007.

Clinical Development Program Update

In February 2006, AVANT reported that the TP10 females-only study did not meet the primary endpoint, thus confirming the results for female subjects in the previous TP10 Phase 2 trial. Therefore, given the strong efficacy data in males shown in this previous study, AVANT believes there is a clear clinical development pathway for a males-only indication for TP10 in cardiac bypass surgery. Males represent 75% of the U.S. market opportunity in cardiac bypass surgery. AVANT plans to seek a corporate partner to complete development and commercialize TP10.

Also in February 2006, the NIAID of the National Institutes of Health (NIH) initiated a Phase 1/2 in-patient dose-ranging clinical trial aimed at demonstrating the safety and immunogenicity of AVANT's Ty800 typhoid fever vaccine. The NIAID trial seeks to confirm the safety and immunogenicity of the Ty800 single dose, oral vaccine observed in an earlier physician-sponsored Ty800 vaccine study.

AVANT has additionally been advancing the preclinical development of other vaccines in its portfolio, and expects to file an Investigational New Drug application in the fourth quarter of 2006 to initiate Phase 1 human safety studies in early 2007 of its oral plague vaccine candidate.

Furthermore, AVANT expects to launch a Phase 3 clinical study in early 2007 for its oral cholera vaccine, CholeraGarde(R), for the travelers' market while planning for additional studies with a partner to address global health needs. In 2005, AVANT with its partner, the International Vaccine Institute (IVI), announced the successful completion of a Phase 2 trial CholeraGarde(R), AVANT's cholera vaccine, in Bangladesh where cholera is endemic. The researchers found the single dose, oral vaccine to be well tolerated and highly immunogenic, with 77% of children aged 9 months to 5 years and over 70% of adults generating protective immune responses. There are currently no licensed cholera vaccines indicated for use in children under age two anywhere in the world.

With respect to AVANT's CETP program for cholesterol management, in preclinical studies AVANT identified a new adjuvant for the vaccine that elicits more than a 10-fold increase in anti-CETP antibody titers when compared to the previous CETi-1 vaccine in animal studies. AVANT has received GMP peptide for the newly formulated vaccine and expects to complete release and stability studies in 2006. AVANT is seeking a development partner for this program.

Finally, AVANT initiated late last fall a new development program that applies its proprietary bacterial vector technologies to the development of a single-dose, oral vaccine against Avian flu. The combination of conserved antigens together with its existing vaccine technologies, could lead to an Avian flu vaccine with product characteristics ideal for mass vaccinations: safe and effective, single-dose, oral, and storable at room temperature. AVANT is currently evaluating a number of Avian flu constructs in pre-clinical animal models to determine their immunogenicity and, if successful, would hope to select a vaccine candidate within 6-12 months.

Manufacturing: AVANT has made significant progress in terms of manufacturing at its Fall River facility in recent months. The manufacture of clinical trial supplies of the oral plague vaccine was completed. AVANT is currently manufacturing CholeraGarde(R) for a planned Phase 3 study for the travelers' vaccine market. When that manufacturing task is done, AVANT will begin making clinical trial supplies of Ty800 for a Phase 2 study planned to start in early 2007.

Webcast and Conference Call

Dr. Ryan and Mr. Catlin will host a conference call and live audio webcast at 11:00 AM EDT on Wednesday, August 2, 2006 to discuss AVANT's Second Quarter and Six-Month financial results. To access the conference call, dial 866-770-7125 (within the United States), or 617-213-8066 (if calling from outside the U.S.). The passcode for participants is 79009907. An audio replay will be available approximately two hours after the call for approximately one week and can be accessed by dialing 888-286-8010 (within the U.S.), or 617-801-6888 (if calling from outside the U.S.). The passcode I.D. number is 52485000. The replay will also be broadcast via the Company's website www.avantimmune.com approximately two hours after the live call. Additionally, a copy of this press release is available by contacting Investor Relations at [phone].

About AVANT Immunotherapeutics, Inc.

AVANT Immunotherapeutics, Inc. discovers and develops innovative vaccines and therapeutics that harness the human immune system to prevent and treat disease. AVANT has three products on the market and six of AVANT's products are in clinical development, including a treatment to reduce complement- mediated tissue damage associated with cardiac bypass surgery and a novel vaccine for cholesterol management. AVANT is also developing a pipeline of products for biodefense, travelers' vaccines, global health, and pandemic flu needs based on AVANT's rapid-protecting, single-dose, oral and temperature stable vaccine technology.

Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: http://www.avantimmune.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that are subject to a variety of risks and uncertainties and reflect AVANT's current views with respect to future events and financial performance. There are a umber of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by AVANT. These factors include, but are not limited to: (1) the integration of multiple technologies and programs; (2) the ability to adapt AVANT's vectoring systems to develop new, safe and effective orally administered vaccines against anthrax and plague or other any other microbes used as bioweapons and other disease causing agents; (3) the ability to successfully complete development and commercialization of TP10, CETi-1, CholeraGarde(R) (Peru-15), Ty800 and other products; (4) the cost, timing, scope and results of ongoing safety and efficacy trials of TP10, CETi-1, CholeraGarde(R) (Peru-15), Ty800 and other preclinical and clinical testing; (5) the ability to successfully complete product research and further development, including animal, pre-clinical and clinical studies of TP10, CETi-1, CholeraGarde(R) (Peru-15), Ty800 and other products; (6) the ability of the Company to manage multiple late stage clinical trials for a variety of product candidates; (7) the volume and profitability of product sales of Megan(R)Vac 1, Megan(R)Egg and other future products; (8) the process of obtaining regulatory approval for the sale of Rotarix(R) in major commercial markets, as well as the timing and success of worldwide commercialization of Rotarix(R) by our partner, Glaxo; (9) Glaxo's strategy and business plans to launch and supply Rotarix(R) worldwide, including in the U.S. and other major markets; (10) changes in existing and potential relationships with corporate collaborators; (11) the availability, cost, delivery and quality of clinical and commercial grade materials supplied by contract manufacturers; (12) the timing, cost and uncertainty of obtaining regulatory approvals to use TP10, CETi-1, CholeraGarde(R) (Peru-15) and Ty800, among other purposes, for adults undergoing cardiac surgery, to raise serum HDL cholesterol levels and to protect travelers and people in endemic regions from diarrhea causing diseases, respectively; (13) the ability to obtain substantial additional funding; (14) the ability to develop and commercialize products before competitors and that are superior to the alternatives developed by competitors; (15) the ability to retain certain members of management;(16) AVANT's expectations regarding research and development expenses and general and administrative expenses; (17) DVC's ability to complete clinical trials and perform under its agreement; (18) AVANT's expectations regarding CETP's ability to improve cholesterol levels and AVANT's ability to develop and commercialize CETP; (19) AVANT's expectations regarding cash balances, anticipated royalty payments and expenses, including infrastructure expenses; and (20) other factors detailed from time to time in filings with the Securities and Exchange Commission. You should carefully review all of these factors, and you should be aware that there may be other factors that could cause these differences. These forward-looking statements were based on information, plans and estimates at the date of this report, and we do not promise to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

AVANT IMMUNOTHERAPEUTICS, INC.


CONSOLIDATED
STATEMENTS
OF OPERATIONS Quarter Six Months
DATA Ended June 30, Ended June 30,
----------------------------------------------------------------------
2006 2005 2006 2005
(Unaudited) (Unaudited)
REVENUE
Product
Development and
Licensing
Agreements $17,446 $59,060 $2,637,420 $130,517
Government
Contracts and
Grants 460,523 522,963 960,730 1,389,050
Product Royalties 27,510 55,138 613,816 88,146
----------------------------------------------------------------------

Total Revenue 505,479 637,161 4,211,966 1,607,713
----------------------------------------------------------------------

OPERATING EXPENSE
Research and
Development 4,463,899 3,430,992 8,812,606 7,461,610
General and
Administrative 2,117,192 1,861,095 4,105,706 3,571,879
Amortization of
Acquired
Intangible Assets 248,778 248,778 497,556 497,556
----------------------------------------------------------------------

Total Operating
Expense 6,829,869 5,540,865 13,415,868 11,531,045
----------------------------------------------------------------------

Operating Loss (6,324,390) (4,903,704) (9,203,902) (9,923,332)

Investment
Income, Net 654,091 169,764 934,612 320,894
----------------------------------------------------------------------

Loss before
Provision for
Income Taxes (5,670,299) (4,733,940) (8,269,290) (9,602,438)

Provision for
Income Taxes - - 372,000 -
----------------------------------------------------------------------

Net Loss $(5,670,299) $(4,733,940) $(8,641,290) $(9,602,438)
----------------------------------------------------------------------

Basic and Diluted
Net Loss per
Common Share $(0.08) $(0.06) $(0.12) $(0.13)
----------------------------------------------------------------------
Weighted Average
Common
Shares
Outstanding 74,174,761 74,132,829 74,173,668 74,132,416
----------------------------------------------------------------------



CONDENSED CONSOLIDATED
BALANCE SHEETS June 30, December 31,
----------------------------------------------------------------------
2006 2005
(Unaudited) (Unaudited)
ASSETS
Cash and Cash
Equivalents $53,468,716 $23,419,434
Other Current
Assets 1,523,599 1,185,462
Property and
Equipment, net 7,950,494 5,743,663
Intangible and
Other Assets,
net 5,605,803 6,103,358
------------ ------------
Total Assets $68,548,612 $36,451,917
============ ============

LIABILITIES AND STOCKHOLDERS'
EQUITY
Current
Liabilities $6,595,344 $3,692,743
Long-Term
Liabilities $49,154,474 11,870,051
Stockholders'
Equity 12,798,794 20,889,123
------------ ------------
Total Liabilities and
Stockholders' Equity $68,548,612 $36,451,917
============ ============


SOURCE: AVANT Immunotherapeutics, Inc.

AVANT Immunotherapeutics, Inc.
Una S. Ryan, Ph.D., 781-433-0771
President and CEO
or
AVANT Immunotherapeutics, Inc.
Avery W. Catlin, 781-433-0771
Chief Financial Officer
[e-mail]
or
For Media:
Kureczka/Martin Associates
Joan Kureczka, 415-821-2413
[e-mail]